Navigation Links
Research 2.0 Updates Coverage of Viral Genetics with Research Report Focused on VG Energy
Date:6/15/2011

SAN MARINO, Calif., June 15, 2011 /PRNewswire/ -- Viral Genetics, Inc., (Pinksheets: VRAL) is pleased to announce that Boston-based Research 2.0 today released an 8-page report focused on the Company's majority-owned subsidiary, VG Energy, Inc. The report is available on the company's website at www.viralgenetics.com/investors/research20_June2011.php and is also distributed over the internet and through institutional platforms including FactSet, CapitalIQ, and TheMarkets.com.  

Research 2.0 is pioneering a new "open professional" model of investment research which gives companies a direct path to quality independent institutional research coverage via an annual retainer and making that research broadly available to all potential investors on the Internet and in open social and professional online networks.

"As with any coverage like this we will let the report and analysts speak for themselves, but we are very pleased to see the exciting new developments at VG Energy get professionally analyzed, described and evaluated for all of our stakeholders," said Viral Genetics and VG Energy CEO, Haig Keledjian.

About Viral Genetics, Inc.

San Marino, California-based Viral Genetics discovers drug therapies from two platform technologies based on over 60 patents: Metabolic Disruption (MDT) and Targeted Peptides (TPT). Founded in 1994, the biotech company is researching treatments for HIV/AIDS, Lyme Disease, Strep, Staph and drug resistant cancer. A majority-owned subsidiary, VG Energy (www.vgenergy.net), is dedicated to exploring biofuel and agricultural applications for the MDT platform. For more information, visit www.viralgenetics.com.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports, including statements about its VG Energy, Inc. subsidiary. None of Viral Genetics' drug compounds are approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world, nor are any non-pharmaceutical products of VG Energy, Inc. commercialized. While Viral Genetics believes that the forward-looking statements and underlying assumptions reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of any of its drug therapies in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of those drug compounds in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, the successful outcome of such studies or tests, or the successful commercialization of VG Energy, Inc.'s non-pharmaceutical products. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.

Media Contact:
Haig Keledjian
(626) 334-5310
info@viralgenetics.com


'/>"/>
SOURCE Viral Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Best of ASCO Features Two Studies Led by US Oncology Research Affiliated Physicians
2. Viral Genetics Updates HIV/AIDS and Drug Resistant Cancer Research Programs
3. ImpactRx Expands Psychiatry Research Panel to Include Adolescent Psychiatrists
4. Hospital Outcomes Research Named "Article of the Year"
5. 2011 mHealth Summit: Call for Research Abstracts and Speakers Now Open
6. BGI Releases a Complete De Novo E. Coli O104 Genome Assembly and is Making Its Detection Kit Protocols and Synthesized Primers Freely Available to Worldwide Disease Control and Research Agencies
7. A Recent Study by ITGs Majestic Market Research Indicates a Strong Launch for Gilenya in Spite of Its Time-Consuming Initiation Process
8. US Oncology Research Affiliated Physicians to Present at 2011 ASCO Annual Meeting
9. Cancer Research UK Signs Deal With Centella Therapeutics, Inc. to Launch Clinical Development of Radiotherapy-Enhancing Drug
10. Aldrich Materials Science Endows New Materials Research Society Mid-Career Researcher Award
11. CVS Caremark Research Tailors Consumer Communications to Encourage Better Medication Behavior
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... May 4, 2016 Valeritas Holdings, ... an alternative public offering (APO). This was accomplished via ... Valeritas, Inc. and a private placement of approximately 5 ... per share. Under the terms of the ... Valeritas Holdings, Inc. will trade on the OTC Markets ...
(Date:5/4/2016)... 2016 Research and ... Acute lymphocytic Leukemia Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Lymphocytic Leukemia epidemiology, Acute Lymphocytic ...
(Date:5/3/2016)... 2016  As a teenager, an active and athletic ... damaged his heart. He continued enjoying sports and recreation ... Shepherd,s heart was giving out and he was a ... 2013, the Mesa, Arizona resident ... a heart transplant, the SynCardia TAH-t is the only ...
Breaking Medicine Technology:
(Date:5/4/2016)... , ... May 04, 2016 , ... May kicked off ... people across the United States. Dermatologist Dr. Ellen Turner is encouraging her patients, as ... advice and focus on skin safety and health now and in the future. , ...
(Date:5/4/2016)... ... , ... Recognizing that lifestyle medicine is essential to health and healthcare, ... Katz, MD, MPH, president of the American College of Lifestyle Medicine, as their first ... gratifying,” said Katz. “There is so much opportunity to add years to lives, and ...
(Date:5/4/2016)... ... 2016 , ... Bayco Products has announced the introduction of ... in models NSP-9842XL and NSR-9844XL . , First previewed at SHOT Show ... included CR-123 batteries to produce up to 650 lumens in a variety of ...
(Date:5/4/2016)... ... May 03, 2016 – (PRWEB) May 04, 2016 ... products, today revealed the non-toxic benefits of its Tutti Frutti line ... teething pain is just part of the story. These food-grade, silicone ... PVC-, and phthalate-free. , “Many baby toys contain BPA, harmful ...
(Date:5/4/2016)... ... 2016 , ... Fertility Centers of New England announced today the opening of ... Center provides convenient access to care for patients seeking fertility treatment in Maine. “We ... Comprehensive Care in Portland,” said Fertility Centers of New England President and CEO, Joseph ...
Breaking Medicine News(10 mins):